NCT04021056

Brief Summary

This is an ongoing, longitudinal, single centre, observational, retro-prospective clinical cohort study of patients with HCC in usual clinical practice. All the HCC patients diagnosed and treated in Liver Cancer Center, Nanfang Hospital are consecutively collected and followed up.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
3,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2011

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2011

Completed
8.3 years until next milestone

First Submitted

Initial submission to the registry

April 23, 2019

Completed
3 months until next milestone

First Posted

Study publicly available on registry

July 16, 2019

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2019

Completed
3.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

July 16, 2019

Status Verified

July 1, 2019

Enrollment Period

8.7 years

First QC Date

April 23, 2019

Last Update Submit

July 12, 2019

Conditions

Hepatocellular Carcinoma

Outcome Measures

Primary Outcomes (2)

  • Evaluate the overall survival rate of all HCC patients

    In order to identify the potential influence factors of HCC patients survival

    10 years

  • Evaluate the recurrence free survival rate of HCC patients after curative treatments

    In order to identify the potential influence factors of tumor recurrence

    10 years

Interventions

No interventionOTHER

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients diagnosed and treated as HCC in Liver Cancer Center, Nanfang Hospital

You may qualify if:

  • Clinical diagnosis of HCC;
  • Age ≥ 16 years;
  • Received treatment targeting for HCC at least once, including operation, ablation, TACE, sorafenib, radiotherapy, chemotherapy, etc;
  • Good compliance with clinical treatment.

You may not qualify if:

  • Diagnosed as other pathological types such as cholangiocarcinoma, or mixed liver cancer;
  • Received only traditional Chinese medicine or symptomatic supportive treatment; (3) survival time ≤ 7 days;
  • HCC diagnosed after liver transplantation;
  • Poor compliance or important data deficient.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nanfang Hospital

Guangzhou, Guangdong, China

RECRUITING

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Central Study Contacts

Jinlin Hou

CONTACT

jlhousmu@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 23, 2019

First Posted

July 16, 2019

Study Start

January 1, 2011

Primary Completion

August 31, 2019

Study Completion

December 31, 2022

Last Updated

July 16, 2019

Record last verified: 2019-07

Locations

CN(1)